Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
paclitaxel + oxaliplatin + leucovorin + 5-fluorouracil
- Development stage
- Unknown
- Lead developer
- Bristol Myers Squibb
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
This is a four-drug combination chemotherapy regimen consisting of paclitaxel, oxaliplatin, leucovorin (folinic acid), and 5-fluorouracil (5-FU). The regimen is commonly referred to as POFL or POF. It has been investigated primarily for the treatment of advanced or metastatic gastric cancer and pancreatic cancer. Paclitaxel is a microtubule-stabilizing agent that inhibits cell division; oxaliplatin is a platinum-based DNA crosslinker causing apoptosis; 5-fluorouracil is an antimetabolite that inhibits thymidylate synthase and disrupts DNA synthesis; leucovorin enhances the binding of 5-FU to its target enzyme, increasing cytotoxicity. This combination has demonstrated significant activity with manageable toxicity in clinical trials for recurrent/metastatic gastric cancer and advanced pancreatic cancer[1][2][3][4][7][9].
- Other names
- POFLPOFpaclitaxel/oxaliplatin/leucovorin/5-FU
02
Targets
TUBB (Tubulin (alpha and beta subunits))TS (Thymidylate synthase)DNA
Beyond the preview
Go deeper on paclitaxel + oxaliplatin + leucovorin + 5-fluorouracil.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on paclitaxel + oxaliplatin + leucovorin + 5-fluorouracil.